Merck, Samsung rack up data on Humira biosim, setting stage for approval apps

Industry watchers expect biosimilars for AbbVie's ($ABBV) Humira to be the most successful copycat biologics launched in the U.S. and Europe, and that's something Merck ($MRK) and Samsung are trying to get in on. Now, the biosim partners are one step closer, with their knockoff clearing late-stage trials and setting the stage for global regulatory applications. Report | More

Suggested Articles

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

W2O Group and California Life Sciences' new data-driven platform tracks top COVID-19 news and conversations in the life science industry.